Alzheimer's drug analyses, Oslo HIV cure, estrobolome findings, and the Lyrid meteor shower | The Naked Scientists

Executive summary

The Naked Scientists explore four interconnected science stories in this episode. They discuss fresh analyses that question the clinical benefit of anti-amyloid antibodies used to treat early Alzheimer’s disease, clarifying that while these drugs can slow progression, they do not halt or cure the disease. They then cover the Oslo patient, a person cured of HIV after a bone marrow transplant, and what this means for future research and treatment strategies. The episode also examines the estrobolome, a gut microbial system that recycles estrogen, and how industrialized populations and infant feeding practices influence estrogen metabolism. It ends with a guide to the Lyrid meteor shower, explaining its origins from Comet Thatcher and how to observe it under dark skies.

Key insights

• Anti-amyloid therapies slow disease progression but are not curative and carry potential risks.
• Rare HIV cures via bone marrow transplantation demonstrate possible mechanisms but are not widely applicable due to safety concerns.
• Estrobolome research reveals higher estrogen recycling in industrialized populations and formula-fed infants, with potential health implications.
• The Lyrid meteor shower provides an annual celestial event linked to a long-period comet, with practical viewing tips.

Overview

The podcast covers four science stories, ranging from neurodegenerative disease therapy to infectious disease cure cases, gut microbiome metabolism, and a meteor shower observation. The hosts present expert commentary and explain the nuances behind trial results and disease mechanisms, offering a balanced view of what current evidence suggests and where the field may head next.

Alzheimer’s drugs: science, trials and interpretation

The discussion centers on two recently approved anti-amyloid antibodies, lecanemab and donanemab, which remove amyloid from the brain and slow disease progression in phase 3 trials. The speakers note that while this slowdown is meaningful, it is not a cure and cognitive decline persists, albeit more gradually. They reference a new Italian analysis that pooled data from seven antibodies—two with demonstrated benefit and five that did not perform in trials—and concluded that, when lumped together, these drugs may not yield a clinically meaningful overall effect. The speakers caution against “throwing the baby out with the bathwater,” recognizing heterogeneity among drugs and the evolving state of the science. A practicing neurologist compares the results to variations seen in blood-pressure therapies, where different approaches can yield different outcomes, and emphasizes that even modest slowing—potentially equating to around five additional months of maintained cognition—could be valuable for patients and families in real life.

"The best estimates that I've seen are that even though they're definitely not perfect, these drugs slow progression, and that would be the equivalent of about five more months of maintained cognition" - Tara Spires Jones

The hosts discuss ongoing questions about early intervention, patient selection, and the safety profiles of these antibodies, including risks of brain edema and hemorrhage. They highlight that some patients may be asymptomatic or in the very early disease phase when treated, and that the development of blood-based biomarkers now makes earlier detection more feasible. They also note regulator attitudes, such as NICE in the UK considering cost-effectiveness, while regulators may approve use based on clinical benefit, not just economics. The speakers look forward to next-generation therapies that address other targets beyond amyloid and to a broader move beyond amyloid-centric approaches.

"Earlier treatment is better, but these drugs aren't completely safe, and there are important questions about how to identify who will benefit the most" - Chris Smith

Oslo patient and HIV cure prospects

The Oslo patient case is presented as part of a growing class of cure patients whose treatment involves a bone marrow transplant. The transplant replaced the patient’s immune system, which, combined with a donor carrying a mutation that blocks HIV entry into cells, led to viral remission after antiretroviral therapy was stopped. The discussion clarifies that it is the new immune system that appears to eradicate the HIV reservoir, not simply the donor mutation alone. The researchers conducted extensive testing to confirm the replacement of the old immune system across the body, including the gut, which houses a large reservoir of immune cells. While the approach offers a potential blueprint for curing HIV in specific cases, the hosts emphasize that bone marrow transplantation is dangerous and impractical for the millions living with HIV, requiring a donor with a compatible life-threatening condition that justifies the risk.

Quote after section:

"It's more likely that the new incoming bone marrow derived cells attack the existing virus infected immune system and wipe out the HIV reservoir" - Marius Troside, infectious diseases doctor at Oslo University Hospital

The episode discusses the broader implications, including the idea that cures might arise from multiple mechanisms, such as immune responses against viral reservoirs and the potential to develop blood tests that monitor cure status. The researchers stress that while these case studies are encouraging, they do not imply a scalable, universal cure for HIV; nonetheless, they provide crucial clues about how curing strategies could be designed in the future.

"There are probably different mechanisms that could lead to cure, including immune reactions against the viral reservoir and approaches to measure the immune response to the virus" - Marius Troside, infectious diseases doctor

Estrobolome and estrogen recycling across populations

The estrobolome segment discusses how gut microbes can reactivate estrogen excreted into the gut, via the beta-glucuronidase enzyme, leading to reabsorption and systemic circulation. The researchers compared industrialized and non-industrialized populations, finding industrialized groups exhibited higher estrogen recycling capacity, with formula-fed infants showing higher recycling than breastfed infants. The conversation covers possible drivers, including diet, physical activity, early-life exposures, and medications, and notes that both men and women showed similar estrobolomes within populations, suggesting non-hormonal drivers. The implications touch on reproductive health, fertility, and cancer risk, acknowledging that the health consequences of increased estrogen recycling are not yet fully clear and require further study.

"Industrialized populations had much higher estrogen recycling capacity than non industrialized populations" - Rebecca Britton, postdoctoral researcher at Jagiellonian University

The interview underscores that this area may inform future interventions and our understanding of hormone-related diseases, while recognizing the role of diet and other lifestyle factors in shaping the estrobolome across diverse global populations.

Lyrid meteor shower: a celestial spectacle explained

The Lyrid meteor shower is described as one of the oldest recorded, produced when Earth passes through debris left by Comet Thatcher. The particles burn up in Earth’s atmosphere, creating meteors with varying brightness depending on size, with larger particles producing brighter displays. Observing tips include traveling to dark sites away from light pollution, acknowledging the Moon’s phase and its impact on visibility, and guiding observers toward the northeastern sky in the UK during the early hours. The hosts explain that Thatcher has a long orbital period and is expected to return around 2283, though orbital uncertainties persist.

"The Lyrids happen in April every year when we pass through the trail of one of these comets" - Megan Argo, space scientist at the University of Lancashire

They also cover color variations in meteors, noting that color depends on the rock's composition and the atmospheric chemistry, with most meteors appearing white but occasional greens or yellows can be observed due to specific materials.

Closing and takeaways

The episode ends with a tease of a future discussion on flooding and resilience and a reminder for listeners to support the show through donations. The hosts encourage curiosity and emphasize the ongoing optimism in dementia and broader neurodegenerative research alongside ongoing innovations in cancer, infectious disease, and microbiome science.

"I think we will have meaningfully life changing treatments in the next decade or so" - Tara Spires Jones